

Nath Bio-Genes (I) Ltd.

(CIN L01110MH1993PLC072842)

Date-16th June, 2021

The Manager-Listing
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai 400001

The Manager- Listing
National Stock Exchange of India Ltd.,
Exchange Plaza, Bandra-Kurla Complex
Bandra (E)
Mumbai-400051

BSE Code-537291

NSE Code-NATHBIOGEN

Sub: Intimation of Board Meeting to consider Audited Financial Results of the Company for the 4th quarter and financial year ended 31st March 2021 and to consider recommendation of Dividend for the 2020-21, if any.

Ref: Regulation 29 of the SEBI (Listing Obligation and Disclosure Requirement) Regulations, 2015.

Dear Sir/Madam,

Pursuant to Regulation 29 and 33 of the Listing Regulations 2015, Notice is hereby given that a meeting of the Board of Directors of the Company will be held on Thursday, 24th June 2021 to approve the following.

- 1. To consider, approve and take on record Audited Financial Results of the Company for the 4th quarter and year ended 31st March 2021.
- 2. To consider recommendation of Dividend for the year 2020-21, if any subject to Approval of shareholders in ensuing AGM.
- 3. To consider the proposal for buyback of equity shares of the Company, subject to approval of banks and other authorities.

The Company has already closed its "Trading Window" under the Code of Conduct for prevention of Insider Trading from 31st March 2021 and it will re-open on 27th June 2021.

You are requested to take note of the above.

Thanking You.

Yours faithfully, For Nath Bio-Genes (India) Limited,

Devinder Khurana Chief Financial Officer

Summe



Nath House, Nath Road, Aurangabad - 431005 (MS) Tel: 0240-2376314/5/6/7 Email: info@nathseeds.com www.nathbiogenes.com

 ^{1,} Chateau Windsor, 86 Veer Nariman Road, Mumbai - 400020 (MS) Tel: 022-22871001, 22875653/4/5